On July 31, 2019, Arsenal, an American private equity fund, announced its acquisition of Montreal-based company Caprion Biosciences. This acquisition, along with Arsenal’s simultaneous acquisition of HistoGeneX, creates a global leader in immune monitoring, protein characterization, and tissue pathology solutions for immunotherapy and drug development. The combined business will provide a full suite of immune monitoring and biomarker development services, from preclinical through late stage clinical trials and companion diagnostics, to biopharmaceutical organizations globally.
Caprion is the leading provider of specialized flow cytometry immune monitoring and quantitative mass spectrometry proteomics services to the biopharmaceutical industry.
Founded by internationally recognized pathologists leading the shift to precision medicine, HistoGeneX provides pathology and biomarker assessment services spanning the drug development continuum.
Osler, Hoskin & Harcourt LLP advised Caprion Biosciences with a team consisting of Shahir Guindi, Sophie Amyot (Corporate) and Manon Thivierge (Tax).
Key Contact
Former National Co-Chair, Partner, Corporate, Montréal
